Bilix, containing the identity of reverse thinking and novelty

1 Establishment of new drug pipeline with bilirubin platform technology
Securing global competitiveness by increasing corporate value
“I want to give hope to those who are living a difficult life with an incurable disease”

[IB Tomato Lim Seong-ji] “The new drug development industry is a specialized area that is difficult for ordinary investors and shareholders to understand, and it is difficult to deliver accurate information even if public disclosure is made. Even if there is content, the bad examples of some companies that are inflated hinder the development of the Korean pharmaceutical bio industry. Bilix will strive to develop accurate new drugs through high-quality research on the bilirubin platform.”

 Kim Myeong-rip, CEO of Bilix, who served as SK Telecom (017670)  in vitro diagnostics business head,  NanoEntec (039860)  CEO, and  Eutilex (263050) business general manager and research center, showed confidence in the bilirubin platform technology.

Bilirubin is a yellow-brown substance present in bile and is a product produced when hemoglobin, a component of red blood cells, is metabolized when worn-out red blood cells are decomposed. Increased levels of bilirubin cause jaundice, a yellowing of the skin or whites of the eyes. By measuring the bilirubin level, it is possible to diagnose the presence and degree of diseases such as the liver and biliary tract, so bilirubin was considered an unhealthy substance. Numerous clinicians and scientists have tried to drug bilirubin, but the main reason for their failure is that bilirubin has extremely hydrophobic properties that do not dissolve in water.

Having overcome the limitations of bilirubin with technology, Bilix successfully completed a Series A investment of KRW 14 billion in the first half of 2021, and is currently seeking follow-up investment of up to KRW 30 billion in 2022.